ORPHA:168984
CLAPO syndrome
Publications
86
54.7th percentile
Trials
0
Interventional, condition-specific
Researchers
362
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, complex, vascular syndrome characterized by capillary of the lower lip, lymphatic of the face and neck, asymmetry of face and limbs, and partial or generalized overgrowth involving one or more body segments.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013125
- MeSH:C567763
- OMIM:613089
- UMLS:C2751313
Additional Mondo synonyms (1)
CLAPO syndrome, somatic
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
86 matched papers (82 in last 10 years) Source
- Phenotype characterisedPresent
26 HPO annotations (e.g. Hemihypertrophy; Venous malformation; Macrodactyly) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
26
Associated phenotypes · MONDO:0013125
- Hemihypertrophy
- Venous malformation
- Macrodactyly
- Varicose veins
- Capillary malformation of the lip
Showing 5 of 26 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-27
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
86
86 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
86 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
82 in the last 10 years · medium confidence · 54.7th percentile (publications denominator)
Phrase hits: 58 · MeSH hits: 3
Who's working on it?
362
Distinct author names in 58 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Biesecker LG4 papers · 2022
Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, Bethesda, MD, USA.
Papers in Europe PMC - 02
- 03Agra N3 papers · 2020
Vascular Malformations Section, Institute of Medical and Molecular Genetics, INGEMM-IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.
Papers in Europe PMC - 04Boixeda P3 papers · 2022
Vascular Anomalies Unit, Department of Dermatology, University Hospital Ramon y Cajal, Madrid, Spain.
Papers in Europe PMC - 05López-Gutiérrez JC3 papers · 2022
Department of Pediatric Surgery, Vascular Anomalies Center, University Hospital La Paz, Madrid, Spain.
Papers in Europe PMC - 06Anand R2 papers · 2022
Department of Radio-Diagnosis, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India.
Papers in Europe PMC - 07Ayuso C2 papers · 2018
CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Papers in Europe PMC - 08Baselga E2 papers · 2022
Department of Dermatology, Hospital Sant Joan de Déu, Passeig de Sant Joan de Déu, Barcelona, Spain.
Papers in Europe PMC - 09Buonuomo PS2 papers · 2023
Rare Disease and Medical Genetics Unit, Bambino Gesù Children's Hospital, IRCCS, 00168 Rome, Italy.
Papers in Europe PMC - 10Bustamante A2 papers · 2018
CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 9 September 2026 · last trial check 9 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 54 · after dedupe 53 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 13 · dropped 40 · fetched 2026-07-27
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (13)
- ctis·2022-501102-35-00·Expired·A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early “triple negative” breast cancer
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-503617-30-02·Authorised, ongoing·Boosting recovery through excitation of arousal and awareness in comatose patients: Dose finding study (BREA2KTHROUGH DOSEFINDER)
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-512635-71-00·Cancelled·A PHASE II, OPEN LABEL, RANDOMIZED, NON-COMPARATIVE COHORTS STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RECURRENCE AND HIGH TUMOR MUTATIONAL BURDEN (TMB-H) OR MICROSATELLITE INSTABILITY (MSI-H) (IMperator)
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-507485-10-00·Authorised, recruiting·MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS)
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-510009-16-00·Expired·PHASE 1/2, MULTICENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION CHEMOTHERAPY, AND AS A SINGLE-AGENT CONTINUATION THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS AGED 1 MONTH TO <18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-506365-64-00·Expired·A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
skipped — Beyond per-disease secondary LLM cap
- ctis·2022-503142-41-00·Authorised, ongoing·An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-505507-22-00·Cancelled·PENTALON - Pilot study for the evaluation of [68Ga]Ga-PentixaFor PET imaging for the identification of unilateral adrenal secretion of ALdosterON in patients with primary aldosteronism.
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-508757-75-00·Cancelled·A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-509707-32-00·Expired·Pembrolizumab for locally advanced, irresectable, non-metastatic dMMR colorectal cancers. The PUMA study.
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-508830-33-00·Expired·HER2-PREDICT: Translational study of tumor samples from patients treated with Trastuzumab Deruxtecan (T-DXd; DS-8201a)
skipped — Beyond per-disease secondary LLM cap
- ctis·2022-501428-45-00·Authorised, ongoing·The DEXA-PSYCH Study: Dexamethasone Repurposing for Moderate to Severe Depression - A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Trial
skipped — Beyond per-disease secondary LLM cap
- ctis·2022-500295-60-00·Authorised, ongoing·An ALFA 2101 multicenter randomized phase II study: CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics
skipped — Beyond per-disease secondary LLM cap
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for CLAPO syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("CLAPO syndrome" OR "CLAPO syndrome, somatic") OR (MESH:"CLAPO Syndrome") OR ("CLAPO" OR "CLAPO-related")MeSH descriptor terms unioned into the query: CLAPO Syndrome
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"CLAPO syndrome" OR "CLAPO syndrome, somatic"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T02:16:12.362Z
